LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
The phase I study will evaluate the safety, efficacy and pharmacokinetics of LBH589B in adult patients with advanced solid tumors or Cutaneous T-cell lymphoma
Tumors|Cutaneous T-Cell Lymphoma
DRUG: LBH589
To determine the maximum-tolerated dose of LBH589, 1st cycle
Safety and tolerability assessed by AEs, SAEs and laboratory values., Every 2 weeks|To characterize the pharmacokinetic (PK) profile of LBH589, every 3 cycles|To assess antitumor activity of LBH589, every 2 cycles
The phase I study will evaluate the safety, efficacy and pharmacokinetics of LBH589B in adult patients with advanced solid tumors or Cutaneous T-cell lymphoma